Estrogen-receptor positive breast cancer

This phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal …

This phase II trial is testing whether a combination of palbociclib (a targeted pill), hormone therapy, and HER2-targeted drugs can shrink early-stage breast tumors as effectively as standard chemotherapy before surgery. Postmenopausal women with hormone receptor-positive, HER2-p…

This study looked at whether shutting down the ovaries (ovarian suppression) combined with hormone therapy (tamoxifen or exemestane) could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery t…

This trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a common type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 participants will take part to guide future r…

This study looked at how well older adults (70+) with advanced, hormone-sensitive breast cancer tolerate a combination of palbociclib and either letrozole or fulvestrant. The goal was to see if the treatment is safe and effective in this age group. 93 participants were enrolled, …

This trial tests an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 people with advanced ER+/HER2- breast cancer that has stopped responding to standard treatments. The goal is to see if it is safe and can shrink tumors or slow the disease. The …

This completed phase 2 trial enrolled 180 women with ER-positive, HER2-negative advanced or metastatic breast cancer. Researchers compared two different dosing schedules of the targeted drug palbociclib (100 mg daily vs. 125 mg for 3 weeks on, 1 week off) combined with standard h…

This early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…

This early-phase trial tested a new experimental drug called AZD2014 combined with the standard hormone therapy fulvestrant in 99 people with advanced ER+ breast cancer. The main goals were to check the safety of the combination and find the right dose. Researchers also looked fo…

This study tested a new drug, lasofoxifene, against the standard treatment fulvestrant in 100 women with advanced ER+/HER2- breast cancer that has a specific mutation in the ESR1 gene. The goal was to see if lasofoxifene could delay cancer growth better than fulvestrant. Particip…

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see how long the cancer could be kept from growing. 49 participants took both pil…

This early-phase study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if the drug is safe and how it affects cancer cells before the participants had surgery. The study lasted up to 2.5 …

This pilot study tested whether giving a high dose of focused radiation (APBI) to the tumor before surgery is feasible for older women with early-stage, hormone-sensitive breast cancer. Twenty-two participants received radiation followed by a lumpectomy. The goal was to see if th…

This Phase 3 trial compares a new hormone therapy pill called elacestrant to standard treatments (fulvestrant or aromatase inhibitors) in 478 people with ER+/HER2- advanced breast cancer that worsened after prior CDK4/6 inhibitor therapy. The study measures how long the cancer st…

This study looked at whether metformin, a common diabetes drug, can reduce the thickening of the uterine lining caused by tamoxifen in postmenopausal breast cancer survivors. Sixty women who had been taking tamoxifen for at least a year were given either metformin or a placebo fo…

This study tests whether a special PET scan using a radioactive tracer called FES can accurately detect breast cancer that has spread to lymph nodes under the arm. Researchers will scan 71 people with estrogen-positive breast cancer and compare the results to standard methods. If…

This early-phase study tested whether a 2-week very low-carbohydrate (ketogenic) diet combined with the drug letrozole is feasible and tolerable for people with early-stage estrogen receptor-positive (ER+) breast cancer. 31 postmenopausal women participated before surgery. The go…

This study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal…